Drug-induced QT interval prolongation: mechanisms and clinical management

The prolonged QT interval is both widely seen and associated with the potentially deadly rhythm, Torsades de Pointes (TdP). While it can occur spontaneously in the congenital form, there is a wide array of drugs that have been implicated in the prolongation of the QT interval. Some of these drugs have either been restricted or withdrawn from the market due to the increased incidence of fatal polymorphic ventricular tachycardia. The list of drugs that cause QT prolongation continues to grow, and an updated list of specific drugs that prolong the QT interval can be found at www.qtdrugs.org. This review focuses on the mechanism of drug-induced QT prolongation, risk factors for TdP, culprit drugs, prevention and monitoring of prolonged drug-induced QT prolongation and treatment strategies.

[1]  C. Obejero-Paz,et al.  Mechanisms of arsenic-induced prolongation of cardiac repolarization. , 2004, Molecular pharmacology.

[2]  Michael Christiansen,et al.  The genetic basis of long QT and short QT syndromes: A mutation update , 2009, Human mutation.

[3]  G. Breithardt,et al.  Electrocardiographic risk stratification in families with congenital long QT syndrome. , 2006, European heart journal.

[4]  F. Casazza,et al.  [Torsade de pointes caused by tricyclic antidepressive agents. Description of a clinical case]. , 1986, Giornale italiano di cardiologia.

[5]  M Restivo,et al.  Mechanism of arrhythmogenicity of the short-long cardiac sequence that precedes ventricular tachyarrhythmias in the long QT syndrome. , 1999, Journal of the American College of Cardiology.

[6]  P. Coumel,et al.  C-terminal HERG mutations: the role of hypokalemia and a KCNQ1-associated mutation in cardiac event occurrence. , 1999, Circulation.

[7]  G. Breithardt,et al.  Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients , 2004, Journal of Molecular Medicine.

[8]  W. Waring,et al.  Evaluation of a QT nomogram for risk assessment after antidepressant overdose. , 2010, British journal of clinical pharmacology.

[9]  A. Moss,et al.  Assessment of the Stability of the Individual‐Based Correction of QT Interval for Heart Rate , 2005, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[10]  QTc Interval Screening in Methadone Treatment , 2009, Annals of Internal Medicine.

[11]  K. Swartz,et al.  Towards a structural view of gating in potassium channels , 2004, Nature Reviews Neuroscience.

[12]  P. Kowey,et al.  Comparison of QTinno, a fully automated electrocardiographic analysis program, to semiautomated electrocardiographic analysis methods in a drug safety study in healthy subjects. , 2009, Journal of electrocardiology.

[13]  A. Arya.  Gender‐Related Differences in Ventricular Repolarization: Beyond Gonadal Steroids , 2005, Journal of cardiovascular electrophysiology.

[14]  A J Levi,et al.  The electrophysiological characteristics of hypertrophied ventricular myocytes from the spontaneously hypertensive rat , 1993, Journal of hypertension.

[15]  K. Ellenbogen,et al.  Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. , 1996, Circulation.

[16]  W. Vieweg.  New Generation Antipsychotic Drugs and QTc Interval Prolongation. , 2003, Primary care companion to the Journal of clinical psychiatry.

[17]  C. Ching,et al.  Congenital long QT syndromes: clinical features, molecular genetics and genetic testing , 2006, Expert review of molecular diagnostics.

[18]  D. Roden,et al.  Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. , 1996, Circulation.

[19]  R. Lazzara.  Amiodarone and torsade de pointes. , 1989, Annals of internal medicine.

[20]  M. Rosen,et al.  Sex, hormones, and repolarization. , 2002, Cardiovascular research.

[21]  G. Breithardt,et al.  Life-threatening Arrhythmias Genotype-phenotype Correlation in the Long-qt Syndrome : Gene-specific Triggers for Genotype-phenotype Correlation in the Long-qt Syndrome Gene-specific Triggers for Life-threatening Arrhythmias , 2022 .

[22]  N. Edvardsson,et al.  Torsade de pointes tachycardias induced by overdosage of zimeldine. , 1989, Journal of cardiovascular pharmacology.

[23]  Bradford Ld.  CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. , 2002 .

[24]  A. Camm,et al.  Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval , 2002, Heart.

[25]  J. Idle,et al.  The role of individual human cytochromes P450 in drug metabolism and clinical response. , 1992, Trends in pharmacological sciences.

[26]  J. N. Black,et al.  Quinine May Trigger Torsades de Pointes During Astemizole Therapy , 1997, Pacing and clinical electrophysiology : PACE.

[27]  J. Schussler,et al.  Cardiac Arrest Due to Torsades De Pointes in a Patient with Complete Heart Block: The “R-On-T” Phenomenon , 2010, Proceedings.

[28]  Kimberly Crimin,et al.  Dynamic Beat-to-Beat Modeling of the QT-RR Interval Relationship: Analysis of QT Prolongation during Alterations of Autonomic State versus Human Ether a-go-go-Related Gene Inhibition , 2005, Journal of Pharmacology and Experimental Therapeutics.

[29]  B. Darpo,et al.  Comparison of Manual and Automated Measurements of the QT Interval in Healthy Volunteers: An Analysis of Five Thorough QT Studies , 2009, Clinical pharmacology and therapeutics.

[30]  C. Hsia,et al.  Azithromycin‐Induced Torsade De Pointes , 2007, Pacing and clinical electrophysiology : PACE.

[31]  A. Hoes,et al.  Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. , 2005, European heart journal.

[32]  E. Antman,et al.  Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. , 1990, Circulation.

[33]  C. Michael Stein,et al.  Oral erythromycin and the risk of sudden death from cardiac causes , 2004 .

[34]  Morrison Hodges,et al.  Rate Correction of the QT Interval , 1997 .

[35]  Craig T. January,et al.  Early Afterdepolarizations: Mechanism of Induction and Block A Role for L‐Type Ca2+ Current , 1989, Circulation research.

[36]  J. Bergin,et al.  Sudden cardiac death in heart failure. , 2000, The Journal of cardiovascular nursing.

[37]  R. Califf,et al.  Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. , 2002, American heart journal.

[38]  A. Moss,et al.  QT Interval: How to Measure It and What Is “Normal” , 2006, Journal of cardiovascular electrophysiology.

[39]  B. Olshansky,et al.  N-acetyl procainamide causing torsades de pointes. , 1982, The American journal of cardiology.

[40]  R. Passman,et al.  Polymorphic ventricular tachycardia, long Q-T syndrome, and torsades de pointes. , 2001, The Medical clinics of North America.

[41]  M. Lehmann,et al.  Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. , 1993, JAMA.

[42]  B. Guglielmo,et al.  The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? , 2010, Journal of hospital medicine.

[43]  Lawrence J Hickey,et al.  The Effect of Moxifloxacin on QTc and Implications for the Design of Thorough QT Studies , 2008, Clinical pharmacology and therapeutics.

[44]  G Duker,et al.  Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? , 1997, The Journal of pharmacology and experimental therapeutics.

[45]  B. Pitt,et al.  Disopyramide-induced ventricular tachycardia. , 1980, Archives of internal medicine.

[46]  D. Snyders,et al.  Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. , 1990, Circulation.

[47]  A J Moss,et al.  Spectrum of Mutations in Long-QT Syndrome Genes: KVLQT1, HERG, SCN5A, KCNE1, and KCNE2 , 2000, Circulation.

[48]  International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. , 2005, Federal register.

[49]  Borje Darpo,et al.  THEMED SECTION: QT SAFETY REVIEW The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance , 2010 .

[50]  M. Lehmann,et al.  The long QT syndrome family of cardiac ion channelopathies: A HuGE review* , 2006, Genetics in Medicine.

[51]  Michael J Ackerman,et al.  Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. , 2010, Circulation.

[52]  D. Roden,et al.  Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. , 1986, American heart journal.

[53]  A H Glassman,et al.  Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. , 2001, The American journal of psychiatry.

[54]  D. Wysowski,et al.  Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and food and drug administration regulatory actions , 2001, American Journal of Gastroenterology.

[55]  E. Aliot,et al.  The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. , 1988, Progress in cardiovascular diseases.

[56]  Dan M. Roden,et al.  Clinical practice. Long-QT syndrome. , 2008, The New England journal of medicine.

[57]  D. Roden,et al.  Exaggerated QT prolongation after cardioversion of atrial fibrillation. , 1999, Journal of the American College of Cardiology.

[58]  C. Conde,et al.  Inhalatory pentamidine therapy and the duration of the QT interval in HIV-infected patients. , 1997, International journal of cardiology.

[59]  M. Lehmann,et al.  Sex difference in risk of torsade de pointes with d,l-sotalol. , 1996, Circulation.

[60]  A. Paulussen,et al.  Pharmacogenomics and acquired long QT syndrome. , 2005, Pharmacogenomics.

[61]  V. Piotrovsky,et al.  Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation , 2005, The AAPS Journal.

[62]  P. Kannankeril.  Understanding drug-induced torsades de pointes: a genetic stance , 2008, Expert opinion on drug safety.

[63]  David Zeltser,et al.  Drug-induced prolongation of the QT interval. , 2004, The New England journal of medicine.

[64]  S. Viskin,et al.  Torsade de Pointes Due to Noncardiac Drugs: Most Patients Have Easily Identifiable Risk Factors , 2003, Medicine.

[65]  M. Malik,et al.  Comparison of Formulae for Heart Rate Correction of QT Interval in Exercise Electrocardiograms , 1999, Pacing and clinical electrophysiology : PACE.

[66]  R. Califf,et al.  Practice Standards for Electrocardiographic Monitoring in Hospital Settings: An American Heart Association Scientific Statement From the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young , 2004, Circulation.

[67]  A. Camm,et al.  Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. , 1999, The New England journal of medicine.

[68]  I. Khan.  Clinical and therapeutic aspects of congenital and acquired long QT syndrome. , 2002, The American journal of medicine.

[69]  D. Tzivoni,et al.  Drug Therapy For Torsade de Pointes , 1993, Journal of cardiovascular electrophysiology.

[70]  Jamie I Vandenberg,et al.  Human ether-a-go-go related gene (hERG) K+ channels: function and dysfunction. , 2008, Progress in biophysics and molecular biology.

[71]  D. Kass,et al.  Sudden cardiac death in heart failure. The role of abnormal repolarization. , 1994, Circulation.

[72]  D. Roden,et al.  Drug Block of I Kr : Model Systems and Relevance to Human Arrhythmias , 2001, Journal of cardiovascular pharmacology.

[73]  R. Owens.  QT prolongation with antimicrobial agents: understanding the significance. , 2004, Drugs.

[74]  L. D. Bradford,et al.  CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. , 2002, Pharmacogenomics.

[75]  Mark A. Wood,et al.  Efficacy and Safety of Repeated Intravenous Doses of Ibutilide for Rapid Conversion of Atrial Flutter or Fibrillation , 1996 .

[76]  R. Owen,et al.  QTc Prolongation by Grapefruit Juice and Its Potential Pharmacological Basis: HERG Channel Blockade by Flavonoids , 2005, Circulation.

[77]  G K Isbister,et al.  Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram. , 2007, QJM : monthly journal of the Association of Physicians.

[78]  M. Sanguinetti,et al.  hERG potassium channels and cardiac arrhythmia , 2006, Nature.

[79]  D. Roden,et al.  Normalization of acquired QT prolongation in humans by intravenous potassium. , 1997, Circulation.

[80]  M. Sanguinetti,et al.  SYMPOSIUM REVIEW: Revealing the structural basis of action of hERG potassium channel activators and blockers , 2010, The Journal of physiology.

[81]  H. Persson,et al.  Citalopram overdose--review of cases treated in Swedish hospitals. , 1997, Journal of toxicology. Clinical toxicology.

[82]  Y. Kuryshev,et al.  Antimony-Based Antileishmanial Compounds Prolong the Cardiac Action Potential by an Increase in Cardiac Calcium Currents , 2006, Molecular Pharmacology.

[83]  Y. Kuryshev,et al.  Pentamidine-Induced Long QT Syndrome and Block of hERG Trafficking , 2005, Journal of Pharmacology and Experimental Therapeutics.

[84]  C. Valdivia,et al.  Drug‐induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine , 2006, British journal of pharmacology.

[85]  Derick R. Peterson,et al.  Increased Risk of Arrhythmic Events in Long-QT Syndrome With Mutations in the Pore Region of the Human Ether-a-go-go–Related Gene Potassium Channel , 2002, Circulation.

[86]  A. Camm,et al.  QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability. , 2002, American journal of physiology. Heart and circulatory physiology.

[87]  N. Moore,et al.  Atypical Antipsychotics , 2005, Drug safety.

[88]  P. C. Viswanathan,et al.  Genetics of acquired long QT syndrome. , 2005, The Journal of clinical investigation.

[89]  S. Tang,et al.  QT prolongation and Torsades de Pointes associated with clarithromycin. , 1998, The American journal of medicine.

[90]  Allen J. Taylor,et al.  Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients. , 1994, Chest.

[91]  D. Roden,et al.  Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. , 2001, The Journal of pharmacology and experimental therapeutics.

[92]  R. Woosley,et al.  Mechanism of cardiotoxicity of halofantrine , 2000, Clinical pharmacology and therapeutics.

[93]  B McNutt,et al.  Torsades de pointes occurring in association with terfenadine use. , 1991, JAMA.

[94]  Christopher Welsh,et al.  Methadone-associated Q-T interval prolongation and torsades de pointes. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.